Business Description
NervGen Pharma is a Canadian drug development company focused on helping the nervous system heal after injury or disease. Its lead drug, NVG-291, is currently being tested in clinical trials for conditions such as spinal cord injury, stroke, multiple sclerosis, and Alzheimer's disease, while a second compound, NVG-300, is in earlier-stage research. The company holds a licensing agreement with Case Western Reserve University covering patented technology that targets nerve damage repair.
